Journal Mobile Options
Table of Contents
Vol. 32, No. 3, 2010
Issue release date: September 2010
Free Access
Am J Nephrol 2010;32:226–233
(DOI:10.1159/000317544)

Impact of Reduced Kidney Function on Cardiopulmonary Fitness in Patients with Systolic Heart Failure

McCullough P.A.a · Franklin B.A.a · Leifer E.b · Fonarow G.C.c · for the HF-ACTION Investigators
aWilliam Beaumont Hospital, Royal Oak, Mich., bNational Heart, Lung and Blood Institute, Bethesda, Md., and cRonald Reagan-UCLA Medical Center, Los Angeles, Calif., USA
email Corresponding Author

Abstract

Background: Decreased renal function has been consistently associated with increased mortality among patients with systolic heart failure. The relationship between estimated glomerular filtration rate (eGFR) and other high-risk features including reduced cardiorespiratory fitness has not been previously reported in this patient population. Methods: The HF-ACTION trial was a prospective, randomized trial of exercise therapy versus usual care in patients with systolic heart failure. Patients with class 2–4 heart failure and a left ventricular ejection fraction of ≤35% were recruited. Serum creatinine was measured up to 1 year prior to entry. The 4-variable modified Modification of Diet in Renal Disease equation was used to calculate eGFR. Peak oxygen consumption (peak VO2) was directly measured using gas exchange analysis during progressive exercise testing to volitional fatigue or adverse signs/symptoms. Results: Of 2,091 subjects (mean age 59 ± 13 years, with serum creatinine available at baseline), 72% were men, and 61, 33, and 5% were Caucasians, African Americans, and others, respectively. Older age, diabetes, and hypertension were all more frequent with declining eGFR. The Pearson correlation between eGFR and peak VO2 was 0.22 (p < 0.0001). Age was negatively correlated with both eGFR (r = –0.44, p < 0.0001) and peak VO2 (r = –0.27, p < 0.0001). The peak VO2 tended to decline across decreasing levels of eGFR. Individuals with an eGFR <30 ml/min/1.73 m2 had, on average, 2.1 high-risk features including peak VO2 <14 ml/kg/min, age >75 years, diabetes, and functional class 3–4 symptoms. Conversely, those with an eGFR >90 ml/min/1.73 m2 had relatively few (1.0) high-risk characteristics. Conclusions: Reduced renal filtration is associated with impaired cardiorespiratory fitness and a clustering of high-risk features in systolic heart failure patients which portend a more complicated course and higher all-cause mortality.


 Outline


 goto top of outline Key Words

  • Heart failure
  • Chronic kidney disease
  • Cardiopulmonary fitness
  • Glomerular filtration rate
  • Renal insufficiency
  • Mortality risk

 goto top of outline Abstract

Background: Decreased renal function has been consistently associated with increased mortality among patients with systolic heart failure. The relationship between estimated glomerular filtration rate (eGFR) and other high-risk features including reduced cardiorespiratory fitness has not been previously reported in this patient population. Methods: The HF-ACTION trial was a prospective, randomized trial of exercise therapy versus usual care in patients with systolic heart failure. Patients with class 2–4 heart failure and a left ventricular ejection fraction of ≤35% were recruited. Serum creatinine was measured up to 1 year prior to entry. The 4-variable modified Modification of Diet in Renal Disease equation was used to calculate eGFR. Peak oxygen consumption (peak VO2) was directly measured using gas exchange analysis during progressive exercise testing to volitional fatigue or adverse signs/symptoms. Results: Of 2,091 subjects (mean age 59 ± 13 years, with serum creatinine available at baseline), 72% were men, and 61, 33, and 5% were Caucasians, African Americans, and others, respectively. Older age, diabetes, and hypertension were all more frequent with declining eGFR. The Pearson correlation between eGFR and peak VO2 was 0.22 (p < 0.0001). Age was negatively correlated with both eGFR (r = –0.44, p < 0.0001) and peak VO2 (r = –0.27, p < 0.0001). The peak VO2 tended to decline across decreasing levels of eGFR. Individuals with an eGFR <30 ml/min/1.73 m2 had, on average, 2.1 high-risk features including peak VO2 <14 ml/kg/min, age >75 years, diabetes, and functional class 3–4 symptoms. Conversely, those with an eGFR >90 ml/min/1.73 m2 had relatively few (1.0) high-risk characteristics. Conclusions: Reduced renal filtration is associated with impaired cardiorespiratory fitness and a clustering of high-risk features in systolic heart failure patients which portend a more complicated course and higher all-cause mortality.

Copyright © 2010 S. Karger AG, Basel


goto top of outline Introduction

We are in the midst of concurrent chronic disease epidemics of congestive heart failure (HF) and chronic kidney disease (CKD) worldwide [1,2]. This is marked by increases in incident and prevalent cases of both diseases over the past several decades driven by rising rates of common risk factors for both CKD and HF including obesity, metabolic syndrome, diabetes, and hypertension [3,4,5,6]. Measures of renal function can now be calculated with a reasonable degree of accuracy with the use of multivariate equations based on serum creatinine and other demographic variables including age [7]. Previous studies have consistently reported an association between reduced estimated glomerular filtration rate (eGFR) and increased HF mortality [8]. We sought to more fully explain the risk features clustered in those patients with CKD and HF while adjusting for age, cardiorespiratory fitness, and other baseline variables in a large, multicenter randomized trial.

 

goto top of outline Methods

goto top of outline Setting

The Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was a prospective, randomized trial of exercise training in patients who were medically stable, with New York Heart Association (NYHA) class 2–4 HF and measured left ventricular ejection fraction ≤35%. Recruitment methods for the HF-ACTION have been published elsewhere [9]. The trial was designed to evaluate the composite end point of all-cause mortality and all-cause hospitalization over a median follow-up of 30 months in patients who underwent medically supervised and home-based exercise training as compared with controls who received usual care [10].

goto top of outline Study Sample

A total of 2,331 subjects were recruited from April 2003 through February 2007 at 82 sites within the United States, Canada, and France; however, the study sample was reduced because 240 subjects had no measured serum creatinine recorded at baseline. The remaining 2,091 HF patients served as the study population, providing complete data for analysis. Major exclusion criteria were comorbidities that could interfere with exercise training (e.g. peritoneal dialysis or hemodialysis) and major cardiovascular events within the last 6 months.

goto top of outline Data Collection

Baseline demographics, clinical history, and objective assessment of clinical signs were gathered by trained research personnel at each site. Subjects underwent peak or symptom-limited cardiopulmonary exercise testing as previously described using a modified Naughton treadmill protocol or a 10 W/min incremental cycle ergometry protocol [11]. Heart rate was measured at rest in the supine and standing positions, during each stage of exercise, and throughout a 6-min recovery. Test termination criteria included: patient request; volitional fatigue; increasing chest or leg pain, and electrocardiographic (ECG) abnormalities (≧2 mm ST segment depression and/or threatening ventricular arrhythmias).

Respiratory variables, heart rate, and perceived exertion were determined at submaximal and peak exercise. The ECG was monitored continuously by oscilloscope, with 3-channel (V1, V5, and aVF) recordings obtained throughout the exercise test, and 12-lead ECGs (1 mV/10 mm) recorded at the end of each stage and during peak exercise. Perception of the intensity of physical effort at submaximal and peak exercise was obtained using the Borg category scale (6–20) [12].

Metabolic data were gathered from standard cardiopulmonary exercise training systems which include a computer assembly for breath-by-breath and on-line 60-second calculations of oxygen consumption (VO2; ml/kg/min or METs), minute ventilation (VE), carbon dioxide production (VCO2), and respiratory exchange ratio (RER; VCO2/VO2). Before each test, the pneumotachometer was referenced according to manufacturer specifications, and the gas analyzers were calibrated with a certified air mixture representing room air (21% O2 and balance nitrogen) and certified oxygen/carbon dioxide concentrations.

The V-slope method, used by experienced investigators at the HF-ACTION core lab, was applied to determine the ventilatory-derived anaerobic threshold (i.e. the break point in linearity when VCO2 was plotted as a function of VO2), expressed as a percentage of the peak VO2. This method has been reported to be a sensitive, reliable, noninvasive technique for the detection of the onset of metabolic acidosis [13,14]. The peak VO2 was defined as the highest VO2 value for a given 15- or 20-second interval within the last 90 s of exercise or the first 30 s of recovery [11]. We also computed the slopes of the relation between VE and VO2, and between VE and VCO2, as markers of breathing economy and functional limitations, respectively.

goto top of outline Calculation of Glomerular Filtration Rate

Measurement of serum creatinine was obtained from the recorded serum creatinine (up to 1 year prior to study enrollment) and performed using the central laboratory at each center. eGFRs (ml/min/1.73 m2) were calculated using the Levey modified Modification of Diet in Renal Disease formula [186.3 × (serum creatinine–1.154) × (age–0.203)]; calculated values were multiplied by 0.742 for women and by 1.21 for African Americans [7]. Calculated eGFR values were categorized as <30, 30–59, 60–89, and ≧90 ml/min/1.73 m2 based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative classification of kidney function; eGFR values <60 ml/min/1.73 m2 were considered abnormal and indicative of moderately reduced kidney function.

goto top of outline Statistical Analysis

Baseline characteristics were reported in counts and proportions or means ± standard deviations as appropriate. The Pearson correlation coefficient was used for bivariate correlations of continuous variables, and the Spearman correlation coefficient was used for bivariate correlations of continuous variables with eGFR category. The Pearson correlation was used to evaluate the bivariate relationship between eGFR and peak VO2 as continuous variables. The Cochran-Mantel-Haenszel test was applied to test for trend of categorical variables across eGFR categories. The general linear model was used to evaluate the relevant predictor variables to eGFR as a dependent variable. A p value <0.05 was considered statistically significant.

 

goto top of outline Results

goto top of outline Baseline Characteristics

The demographics for the study sample (n = 2,091) were as follows: age 59 ± 13 years (range 19–90); 72% male; 61% Caucasians, 33% African Americans, and 5% others. Of note, those with advanced CKD were more likely to be Caucasians than African Americans, consistent with a multinational population including Canadian and European sites. Risk factors for HF or CKD included: history of hypertension in 61%, diabetes in 33%, and myocardial infarction in 43%. The baseline characteristics stratified by eGFR level are shown in table 1. Those with advanced CKD tended to be older, and more commonly had higher rates of expected risk factors for both HF and CKD, including hypertension and diabetes. In addition, advanced CKD patients where more likely to have had a prior myocardial infarction or have undergone coronary artery bypass surgery (p < 0.0001 for both).

TAB01
Table 1. Baseline characteristics, by CKD stage

goto top of outline Clinical Examination Variables

Table 2 summarizes the baseline clinical examination variables. Of note, patients had blood pressures that were in the normal range, averaging 114/70 mm Hg. There were no differences in baseline systolic blood pressures across the CKD groups. The severity of HF symptoms as reflected in the NYHA functional classification and the objective impairment in 6-min walk distance tended to be greater in those with reduced eGFR. The degree of left ventricular systolic impairment and dilation tended to be lower across the groups by declining eGFR.

TAB02
Table 2. Clinical examination variables, by CKD stage

goto top of outline Glomerular Filtration Rate and Cardiopulmonary Exercise Test Results

The results of the baseline cardiopulmonary exercise tests, including the mean peak VO2 values per level of eGFR, are shown in table 3. The mean peak VO2 was lower in a graded fashion over cohorts of declining eGFR. In those categories with eGFR <60 ml/min/1.73 m2, the mean peak VO2 values were consistently lower than the population (n = 2,091) median (14.3 ml/kg/min). The mean peak RER was similar across groups, suggesting comparable somatic anaerobiosis and volitional fatigue. The VO2 at the anaerobic threshold and the time to RER = 1.0, however, were both modestly lower in the cohort with the most severely reduced renal function. Figure 1 displays a box plot of the peak VO2 results according to the eGFR category. The Pearson correlation between eGFR and peak VO2 was 0.22 (p < 0.0001). Age was inversely correlated with both eGFR (r = –0.44, p < 0.0001) and peak VO2 (r = –0.27, p < 0.0001).

TAB03
Table 3. Results from cardiopulmonary stress tests

FIG01
Fig. 1. Box plot of eGFR and peak VO2 levels obtained at baseline across CKD groups. IQR = Interquartile range.

goto top of outline Clustering of High-Risk Features

Figure 2 shows the relative cumulative frequency per 1,000 of high-risk features including peak VO2 <14 ml/kg/min, age >75 years, diabetes, and functional class 3–4 symptoms. The relative proportions of older age and peak VO2 <14 ml/kg/min increased in a graded fashion over the lower eGFR categories and were the 2 most frequent high-risk characteristics among those with an eGFR <60 ml/min/1.73 m2. Figure 3 gives the median number of high-risk conditions in patients according to the eGFR category. Among those with eGFR <30 ml/min/1.73 m2, 89% of the subjects had at least 1 high-risk characteristic, and 15% of the subjects had all 4 high-risk features. The highest NYHA class (mean 2.68) characterized those who were in both the lowest peak VO2 quartile (≤11.3 ml/kg/min) and the eGFR category (<30 ml/min/1.73 m2).

FIG02
Fig. 2. Stacked bar graph showing the cumulative frequency per 1,000 subjects of high-risk features stratified by eGFR category.

FIG03
Fig. 3. Median number of high-risk features stratified by eGFR category.

goto top of outline Independent Associations with Significant CKD

Using multiple logistic regression, only age (OR = 1.05 per year increase, 95% CI 1.03–1.08, p < 0.0001) and peak VO2 (OR = 1.18 per 1 ml/kg/min decrease, 95% CI 1.09–1.25, p < 0.0001) were independently associated with a baseline eGFR <30 ml/min/1.73 m2 (stage 4 and higher CKD). When eGFR was modeled as a continuous outcome variable, older age, lower peak VO2, lower left ventricular ejection fraction, higher NHYA functional class, and African American race were all found to be statistically significant (p < 0.05). The overall R2 for the model was 0.23, which can be interpreted as indicating that 23% of the variability in renal filtration function was explained by differences in baseline variables.

 

goto top of outline Discussion

We found that reduced renal function was modestly associated with lower peak VO2 in this baseline analysis. This relationship was highly driven by age as there was a 17-year difference between the highest and the lowest eGFR categories. We believe that cardiac function, more than underlying pulmonary disease, accounted for the severely reduced peak VO2 values, given that 85% of the subjects had no history of chronic obstructive lung disease and all had symptomatic HF. Holding age constant in the multivariate analysis, peak VO2 was independently associated with reduced eGFR. The VO2 at the anaerobic threshold and the time to RER = 1.0 were progressively lower as renal function worsened, suggesting that uremia may be related to insufficient oxygen delivery to activate muscles and the associated lactic acidemia. We do not have published reports of expected cardiopulmonary test results in patients with CKD but normal cardiac function to make comparisons. The categories of eGFR according to the National Kidney Foundation stages of CKD segregated patients into groups with a graded increase in the number and cumulative frequency of combined high-risk features, including older age, diabetes, more severe symptoms, and lower cardiorespiratory fitness. Importantly, significant CKD was independently associated with multiple variables that are associated with increased mortality in patients with HF. We did not have the etiology of CKD recorded and cannot make conclusions on whether one form of CKD is different from another. Nonetheless, these data are consistent with the notion that CKD is a high-risk state for patients with HF and represents a complicated clustering of factors that are related to all-cause mortality [15].

Reduced renal filtration function is associated with salt and water retention and chronic volume overload which may exacerbate HF symptoms. Indeed, those with the most impaired renal function and the lowest peak VO2 had the highest physician-assigned NYHA class and the worst HF symptoms. These patients may indeed have the presence of a chronic cardiorenal syndrome, where either the HF worsens kidney function (type 2) or vice versa (type 4) [16]. In cardiorenal syndromes, uremia may play an additional role in reducing myocardial contractility and systolic performance [17]. Metabolic acidosis associated with progressive renal failure also plays a role in the impairment of cellular transport of electrolytes and oxygen, which affects cardiovascular and cellular functions [18]. Hormonal anomalies in CKD include reduced levels of 1,25-dihydroxyvitamin D and erythropoietin, both of which have been implicated in left ventricular remodeling and HF [19,20]. Lastly, CKD is associated with increased markers of inflammation and oxidative stress [21,22]. Although the clinical significance of these indicators in HF remains unclear, it appears that in those patients with the lowest eGFR, both inflammation and oxidative stress may serve to worsen symptomology and functional capacity. Collectively, these pathologic changes may be responsible, at least in part, for the impaired exercise tolerance in patients with the most compromised eGFR. It has been observed that in end-stage renal disease patients with left ventricular impairment, renal transplantation results in an increase in left ventricular ejection fraction from 32 to 52% and improved functional status, suggesting that CKD is playing a reversible role in the depression of cardiopulmonary performance [23].

We recognize that age is an important confounder for the eGFR measurement (part of the estimating equation) and for peak VO2 (10% per decade decline seen in normal aging) [24]. Age was correlated with both measures in our study, suggesting that the senescent decline in both cardiorespiratory and renal function may play a role in the progression of adverse left ventricular remodeling and attendant HF symptoms [25,26]. Importantly, the triad of older age, low functional capacity, and reduced renal filtration may identify a particularly frail population that is more prone to medication adverse events, complications during hospitalizations, and a greater susceptibility to mortality with major adverse events over the natural history of HF [27,28,29]. The rates of β-blocker use were high (approx. 95%) and similar (p = 0.019) across the eGFR groups and, hence, were unlikely to confound the results. Our data support this notion to some degree with lower rates of angiotensin-converting enzyme inhibitors and higher rates of myocardial infarction and bypass surgery in those with reduced renal function at baseline.

Our study has all the limitations of a cross-sectional analysis from a large randomized trial. Selection bias for entry into the trial invariably yielded a younger and more robust group of HF patients than those normally seen in clinical practice. Our subjects were further restricted to having systolic HF, thus, we cannot generalize our findings to those with pure diastolic HF. Serum creatinine was obtained from clinical records and not measured in a core lab, hence, differences in assay types and standardization invariably contributed to variation in eGFR. Unfortunately, we did not measure arterial blood gas values, levels of vitamin D, or erythropoietin. Moreover, we did not address the complicated issue of anemia, CKD, and HF severity, and did not include hemoglobin in the present analysis, since it has been reserved for future manuscripts. Lastly, we did not have advanced biologic measures of inflammation and oxidative stress or other biomarkers to elucidate the pathophysiologic mechanisms relating chronic failure of both the heart and kidneys [30].

 

goto top of outline Conclusion

Reduced renal filtration function is associated with a markedly impaired functional capacity and a clustering of high-risk features in systolic HF patients which portend a more complicated course and higher all-cause mortality.

 

goto top of outline Acknowledgements

Gregg C. Fonarow is a consultant/honorarium recipient from Novartis (significant), and a honorarium recipient from Merck-Schering Plough (significant). The study was supported/funded by the National Institutes of Health, National Heart, Lung and Blood Institute.


 goto top of outline References
  1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol 2002;39:60–69.
  2. Szczech LA, Harmon W, Hostetter TH, Klotman PE, Powe NR, Sedor JR, Smedberg P, Himmelfarb J: World Kidney Day 2009: problems and challenges in the emerging epidemic of kidney disease. J Am Soc Nephrol 2009;20:453–455.
  3. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators: CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(4 suppl 2):S13–S20.

    External Resources

  4. Whaley-Connell AT, Sowers JR, McFarlane SI, Norris KC, Chen SC, Li S, Qiu Y, Wang C, Stevens LA, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators: Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(4 suppl 2):S21–S29.

    External Resources

  5. Artham SM, Lavie CJ, Patel HM, Ventura HO: Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr 2008;3:155–161.
  6. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA: Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008;37:663–684.
  7. Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180.
  8. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987–1996.
  9. Whellan DJ, O’Connor CM, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Houston-Miller N, Fleg JL, Schulman KA, Piña IL, HF-ACTION Trial Investigators: Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J 2007;153:201–211.
  10. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piña IL, HF-ACTION Investigators: Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439–1450.
  11. Bensimhon DR, Leifer ES, Ellis SJ, Fleg JL, Keteyian SJ, Piña IL, Kitzman DW, McKelvie RS, Kraus WE, Forman DE, Kao AJ, Whellan DJ, O’Connor CM, Russell SD, HF-ACTION Trial Investigators: Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am J Cardiol 2008;102:712–717.
  12. Borg G: Borg’s Perceived Exertion and Pain Scales. Champaigne, Human Kinetics, 1998.
  13. Beaver WL, Wasserman K, Whipp BJ: A new method for detecting the anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–2027.
  14. Sue DY, Wasserman K, Moricca RB, et al: Metabolic acidosis during exercise in patients with chronic obstructive pulmonary disease. Use of the V-slope method for anaerobic threshold determination. Chest 1988;94:931–938.
  15. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives – A position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259.
  16. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, for the Acute Dialysis Quality Initiative (ADQI) consensus group: Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703–711.
  17. Weisensee D, Schnaars Y, Schoeppe W, Bereiter-Hahn J, Löw-Friedrich I: Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro. Exp Nephrol 1997;5:194–200.
  18. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA: Renal dysfunction and acceleration of coronary disease. Heart 2004;90:961–966.
  19. Zittermann A, Schleithoff SS, Koerfer R: Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006;11:25–33.
  20. Smith K, Semple D, Bhandari S, Seymour AM: Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail 2009;11:732–738.
  21. van der Zee S, Baber U, Elmariah S, Winston J, Fuster V: Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009;6:580–589.
  22. Kovesdy CP, Kalantar-Zadeh K: Review article: biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009;14:408–415.
  23. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005;45:1051–1060.
  24. Hawkins S, Wiswell R: Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training. Sports Med 2003;33:877–888.
  25. Anderson S, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kaysen GA, Kusek JW, Nayfield SG, Schmader K, Tian Y, Ashworth JR, Clayton CP, Parker RP, Tarver ED, Woolard NF, High KP, workshop participants: Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 2009;20:1199–1209.
  26. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009;204:298–303.
  27. Franklin BA: Survival of the fittest: evidence for high-risk and cardioprotective fitness levels. Curr Sports Med Rep 2002;1:257–259.

    External Resources

  28. McCullough PA: Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725–728.
  29. 29 Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U: Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004;94:957–960.
  30. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505–521.

 goto top of outline Author Contacts

Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA
Divisions of Cardiology, Nutrition and Preventive Medicine
William Beaumont Hospital, Beaumont Health Center
4949 Coolidge, Royal Oak, MI 48073 (USA)
Tel. +1 248 655 5948, Fax +1 248 655 5901, E-Mail peteramccullough@gmail.com


 goto top of outline Article Information

The study has previously been published as an abstract.

Received: May 8, 2010
Accepted: June 20, 2010
Published online: July 22, 2010
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 3, Number of References : 30


 goto top of outline Publication Details

American Journal of Nephrology

Vol. 32, No. 3, Year 2010 (Cover Date: September 2010)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250-8095 (Print), eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Background: Decreased renal function has been consistently associated with increased mortality among patients with systolic heart failure. The relationship between estimated glomerular filtration rate (eGFR) and other high-risk features including reduced cardiorespiratory fitness has not been previously reported in this patient population. Methods: The HF-ACTION trial was a prospective, randomized trial of exercise therapy versus usual care in patients with systolic heart failure. Patients with class 2–4 heart failure and a left ventricular ejection fraction of ≤35% were recruited. Serum creatinine was measured up to 1 year prior to entry. The 4-variable modified Modification of Diet in Renal Disease equation was used to calculate eGFR. Peak oxygen consumption (peak VO2) was directly measured using gas exchange analysis during progressive exercise testing to volitional fatigue or adverse signs/symptoms. Results: Of 2,091 subjects (mean age 59 ± 13 years, with serum creatinine available at baseline), 72% were men, and 61, 33, and 5% were Caucasians, African Americans, and others, respectively. Older age, diabetes, and hypertension were all more frequent with declining eGFR. The Pearson correlation between eGFR and peak VO2 was 0.22 (p < 0.0001). Age was negatively correlated with both eGFR (r = –0.44, p < 0.0001) and peak VO2 (r = –0.27, p < 0.0001). The peak VO2 tended to decline across decreasing levels of eGFR. Individuals with an eGFR <30 ml/min/1.73 m2 had, on average, 2.1 high-risk features including peak VO2 <14 ml/kg/min, age >75 years, diabetes, and functional class 3–4 symptoms. Conversely, those with an eGFR >90 ml/min/1.73 m2 had relatively few (1.0) high-risk characteristics. Conclusions: Reduced renal filtration is associated with impaired cardiorespiratory fitness and a clustering of high-risk features in systolic heart failure patients which portend a more complicated course and higher all-cause mortality.



 goto top of outline Author Contacts

Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA
Divisions of Cardiology, Nutrition and Preventive Medicine
William Beaumont Hospital, Beaumont Health Center
4949 Coolidge, Royal Oak, MI 48073 (USA)
Tel. +1 248 655 5948, Fax +1 248 655 5901, E-Mail peteramccullough@gmail.com


 goto top of outline Article Information

The study has previously been published as an abstract.

Received: May 8, 2010
Accepted: June 20, 2010
Published online: July 22, 2010
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 3, Number of References : 30


 goto top of outline Publication Details

American Journal of Nephrology

Vol. 32, No. 3, Year 2010 (Cover Date: September 2010)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250-8095 (Print), eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol 2002;39:60–69.
  2. Szczech LA, Harmon W, Hostetter TH, Klotman PE, Powe NR, Sedor JR, Smedberg P, Himmelfarb J: World Kidney Day 2009: problems and challenges in the emerging epidemic of kidney disease. J Am Soc Nephrol 2009;20:453–455.
  3. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators: CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(4 suppl 2):S13–S20.

    External Resources

  4. Whaley-Connell AT, Sowers JR, McFarlane SI, Norris KC, Chen SC, Li S, Qiu Y, Wang C, Stevens LA, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators: Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(4 suppl 2):S21–S29.

    External Resources

  5. Artham SM, Lavie CJ, Patel HM, Ventura HO: Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr 2008;3:155–161.
  6. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA: Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008;37:663–684.
  7. Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180.
  8. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987–1996.
  9. Whellan DJ, O’Connor CM, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Houston-Miller N, Fleg JL, Schulman KA, Piña IL, HF-ACTION Trial Investigators: Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J 2007;153:201–211.
  10. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piña IL, HF-ACTION Investigators: Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439–1450.
  11. Bensimhon DR, Leifer ES, Ellis SJ, Fleg JL, Keteyian SJ, Piña IL, Kitzman DW, McKelvie RS, Kraus WE, Forman DE, Kao AJ, Whellan DJ, O’Connor CM, Russell SD, HF-ACTION Trial Investigators: Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am J Cardiol 2008;102:712–717.
  12. Borg G: Borg’s Perceived Exertion and Pain Scales. Champaigne, Human Kinetics, 1998.
  13. Beaver WL, Wasserman K, Whipp BJ: A new method for detecting the anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–2027.
  14. Sue DY, Wasserman K, Moricca RB, et al: Metabolic acidosis during exercise in patients with chronic obstructive pulmonary disease. Use of the V-slope method for anaerobic threshold determination. Chest 1988;94:931–938.
  15. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives – A position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259.
  16. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, for the Acute Dialysis Quality Initiative (ADQI) consensus group: Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703–711.
  17. Weisensee D, Schnaars Y, Schoeppe W, Bereiter-Hahn J, Löw-Friedrich I: Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro. Exp Nephrol 1997;5:194–200.
  18. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA: Renal dysfunction and acceleration of coronary disease. Heart 2004;90:961–966.
  19. Zittermann A, Schleithoff SS, Koerfer R: Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006;11:25–33.
  20. Smith K, Semple D, Bhandari S, Seymour AM: Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail 2009;11:732–738.
  21. van der Zee S, Baber U, Elmariah S, Winston J, Fuster V: Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009;6:580–589.
  22. Kovesdy CP, Kalantar-Zadeh K: Review article: biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009;14:408–415.
  23. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005;45:1051–1060.
  24. Hawkins S, Wiswell R: Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training. Sports Med 2003;33:877–888.
  25. Anderson S, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kaysen GA, Kusek JW, Nayfield SG, Schmader K, Tian Y, Ashworth JR, Clayton CP, Parker RP, Tarver ED, Woolard NF, High KP, workshop participants: Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 2009;20:1199–1209.
  26. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009;204:298–303.
  27. Franklin BA: Survival of the fittest: evidence for high-risk and cardioprotective fitness levels. Curr Sports Med Rep 2002;1:257–259.

    External Resources

  28. McCullough PA: Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725–728.
  29. 29 Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U: Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004;94:957–960.
  30. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505–521.